after enrollment you receive the study schedule and information about the medications that will be used.

you will undergo baseline assessments that include a physical examination, collection of medical history, blood tests (laboratory tests) and imaging scans to document the current status of the tumor.

the first treatment consists of an intravenous infusion of regn10597 alone or in combination with cemiplimab.

the medication is delivered through a vein using a needle; the exact dose and infusion time are defined by the study protocol.

if combination therapy is assigned, both drugs are given during the same visit.

additional infusions of regn10597 (and possibly cemiplimab) are administered at regular intervals that are specified in the protocol, typically every few weeks.

the dose may be increased in later cycles according to the dose‑escalation design of the study.

each infusion is followed by observation for immediate side effects.

once the dose‑escalation portion is completed, you may continue receiving the same intravenous infusions in the dose‑expansion phase.

the purpose of this phase is to further evaluate the activity of the medicines while using the dose that was found to be safe.

treatment continues for a predefined number of cycles or until disease progression or unacceptable toxicity.

throughout the study you attend clinic visits for safety assessments, which include blood tests and physical examinations.

imaging scans are performed periodically to assess tumor response according to standard criteria.

any side effects are recorded and managed according to the study guidelines.

after the planned treatment period ends, you stop receiving the infusions but continue follow‑up visits.

follow‑up includes periodic blood tests and imaging to monitor long‑term safety and disease status.

the duration of follow‑up is defined by the study protocol.